Compare DAKT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | EVO |
|---|---|---|
| Founded | 1968 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | DAKT | EVO |
|---|---|---|
| Price | $20.79 | $3.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 231.4K | 47.1K |
| Earning Date | 03-04-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | $1.37 |
| Revenue Next Year | $9.16 | $10.05 |
| P/E Ratio | $27.29 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.05 | $2.31 |
| 52 Week High | $28.27 | $4.42 |
| Indicator | DAKT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 56.03 |
| Support Level | $18.76 | $2.88 |
| Resistance Level | $21.14 | $3.75 |
| Average True Range (ATR) | 0.55 | 0.07 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 89.72 | 89.58 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.